What is ketorolac 60 mg used for?
Pharmaceutical Product Monograph: Ketorolac Tromethamine Injection (60 mg/2 mL)
In the pharmaceutical industry, Ketorolac Tromethamine is a high-potency, parenteral Non-Steroidal Anti-Inflammatory Drug (NSAID) of the pyrrolizine carboxylic acid derivative group. As a pharmacist and manufacturer, I view this molecule as a “Non-Opioid Analgesic Powerhouse”—it is technically designed to provide short-term pain relief with an efficacy profile comparable to low-dose Morphine or Meperidine, but without the respiratory depression or addiction potential.
At your WHO-GMP facility in Mumbai, Ketorolac 60 mg/2 mL is a critical Post-Operative and Trauma Care SKU. The 60 mg dose is specifically a Single-Dose loading or treatment dose for acute, severe pain management.
Therapeutic Profile: Primary Indications
Ketorolac is indicated only for the short-term (up to 5 days) management of moderately severe acute pain.
| Indication | Clinical Context | Technical Rationale |
| Post-Surgical Pain | Orthopedic / Gynecological | Opioid Sparing: Used immediately after major surgery to reduce the need for narcotics. |
| Acute Renal Colic | Emergency / Urology | Highly effective at inhibiting the prostaglandins that cause ureteral spasms and intense kidney stone pain. |
| Acute Trauma | ER / Casualty | Provides rapid stabilization for fractures or severe soft-tissue injuries before definitive surgery. |
| Migraine (Refractory) | Neurology | Used in the ER to terminate severe “status migrainosus” when other agents fail. |
Mechanism: Potent COX-1 & COX-2 Inhibition
Ketorolac works by shutting down the “Biological Pain Transmitters” (Prostaglandins):
Enzyme Blockade: It non-selectively inhibits Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes.
Prostaglandin Suppression: It prevents the synthesis of $PGE_2$ and $PGF_{2\alpha}$, which normally sensitize peripheral pain receptors (nociceptors).
Peripheral Action: Unlike opioids, which act on the brain, Ketorolac technically acts at the site of injury, making it an excellent “peripheral” analgesic.
The Pharmacist’s “Technical Warning”
The “5-Day Limit”: As a pharmacist, I must emphasize that Ketorolac is not for chronic use. Continuing treatment beyond 5 days technically spikes the risk of life-threatening gastric perforation and acute renal failure.
The “Bleeding” Alert: Ketorolac is a potent inhibitor of platelet aggregation. It should be used with extreme caution in “bloody” surgeries (like tonsillectomy) or in patients on blood thinners, as it increases the risk of post-operative hemorrhage.
Renal Threshold: It is contraindicated in patients with moderate-to-severe renal impairment ($SCr > 1.4 \text{ mg/dL}$) or those at risk of volume depletion/dehydration.
The “Loading Dose” Clarification: While 60 mg is common as a single IM dose, for patients $>65$ years old or weighing $<50 \text{ kg}$, the maximum single dose is technically capped at 30 mg.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Stability & pH” USP: Ketorolac is highly sensitive to light and requires a precise pH (6.9 to 7.9). On your digital marketplace, highlight your Oxygen-Free Nitrogen Flushing and Amber Type 1 Glass vials. This ensures the solution stays clear and prevents the formation of “related substances” like ketorolac dimers.
The “NSAID-Opioid” Replacement Market: For international B2B tenders (especially in regions fighting the “Opioid Crisis” like North America and Europe), market Ketorolac as a “Narcotic-Sparing Essential.” It is a high-volume procurement item for modern pain clinics.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ketorolac 30 mg/mL and 60 mg/2 mL to support your registration in international B2B tenders for surgical centers.